Mitarbeiterinnen und Mitarbeiter

Jahnz, H., Hamann, M. V., Kim, H., Sun, Y., Quiroz, N. S., Zhu, L., Swaiba, U. E., Foth, D., Beschorner, N., Kumar, P. & Lange, U. C. (2026). Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy bioRxiv. URI

Hamann, M. V., Brauckmann, L., Schwarz, C., Spohn, M., Stoeck, R., Leddy, S. M., Frouard, J., Adiba, M., Winzer, R., Virdi, S., Grundhoff, A., Feschotte, C., Muecksch, F., Roan, N. R., Tolosa, E. & Lange, U. C. (2026). Selective persistence of HIV-1-infected T cell clones can occur through immune reprogramming driven by defective, transcriptionally active proviruses bioRxiv. URI

Hamann MV, Godbole S, Adiba M, Leddy SM, Navolić J, Tabatabai G, Merk DJ, Lange UC, Neumann JE (2025). Expression of LTR and LINE1 transposable elements defines atypical teratoid/rhabdoid tumor subtypes. Acta Neuropathol Commun. 13/2025; PubMed

Hamann MV, Godbole S, Adiba M, Leddy SM, Navolić J, Tabatabai G, Merk DJ, Lange UC, Neumann JE (2025). Expression of LTR and LINE1 transposable elements defines atypical teratoid/rhabdoid tumor subtypes. bioRxiv. 2025 May 14; PubMed

Hamann MV, Adiba M, Lange UC (2023). Confounding factors in profiling of locus-specific human endogenous retrovirus (HERV) transcript signatures in primary T cells using multi-study-derived datasets. BMC Med Genomics. 16/2023; PubMed

Hamann MV, Beschorner N, Vu XK, Hauber I, Lange UC, Traenkle B, Kaiser PD, Foth D, Schneider C, Büning H, Rothbauer U, Hauber J (2021). Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors. PLoS One. 16/2021; PubMed

Hamann MV, Ehmele P, Verdikt R, Bialek-Waldmann JK, Virdi S, Günther T, Van Lint C, Grundhoff A, Hauber J, Lange UC (2020). Transcriptional behavior of the HIV-1 promoter in context of the BACH2 prominent proviral integration gene. Virus Res. 293/2021; PubMed

Camgoz A, Paszkowski-Rogacz M, Satpathy S, Wermke M, Hamann MV, von Bonin M, Choudhary C, Knapp S, Buchholz F (2018). STK3 is a therapeutic target for a subset of acute myeloid leukemias. Oncotarget. 9/2018; PubMed